^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 expression

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061)
    Phase 1
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/16/2019
    Primary completion :
    09/18/2021
    Completion :
    08/19/2022
    CD19
    |
    CD19 expression
    |
    CD19.t-haNK
    A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (BP41072) (NCT04077723)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/13/2019
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    CD20 • CD19
    |
    CD20 expression • CD19 expression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT06124157)
    Phase 3
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/29/2025
    Primary completion :
    12/01/2030
    Completion :
    12/01/2030
    ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R
    |
    CD19 expression
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (NCT01087294)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/04/2010
    Primary completion :
    03/08/2024
    Completion :
    04/02/2024
    CD19
    |
    CD19 expression
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) (NCT05667506)
    Phase 1/2
    Juventas Cell Therapy Ltd.
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/07/2023
    Primary completion :
    07/30/2025
    Completion :
    12/30/2026
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)
    A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (NCT06009107)
    Phase 1/2
    Juventas Cell Therapy Ltd.
    Not yet recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/30/2025
    Primary completion :
    12/30/2026
    Completion :
    12/30/2027
    IL6
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • HY004
    Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/refractory CD19+ ALL and NHL (NCT03373071)
    Phase 1/2
    Bambino Gesù Hospital and Research Institute
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    12/23/2017
    Primary completion :
    05/11/2021
    Completion :
    01/24/2025
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV
    Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL (NCT03751709)
    Phase 1
    Cedars-Sinai Medical Center
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/14/2020
    Primary completion :
    03/27/2023
    Completion :
    11/12/2024
    CD19
    |
    CD19 expression
    |
    Blincyto (blinatumomab)
    Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (NCI-2016-01300) (NCT02879695)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/25/2017
    Primary completion :
    05/22/2023
    Completion :
    07/18/2025
    CD19 • CD34 • MME
    |
    CD19 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)